Xstrahl to Spotlight Superficial and Orthovoltage Radiotherapy Solutions for Skin Cancer and Benign Conditions at ASTRO 2024
Xstrahl to host a presentation by the IORBC: An Introduction to Radiotherapy for Benign Conditions with the IORBC
The Xstrahl 200 is a versatile orthovoltage radiotherapy solution for treating superficial lesions, skin cancers, and benign conditions.
Xstrahl, a global leader in the delivery of superficial and orthovoltage radiation therapy devices and preclinical radiation research systems, will demonstrate Radiant™ Aura, a new low-dose, X-ray based, dual modality radiation therapy option for treating non-melanoma skin cancers (NMSC) and keloid scarring at the American Society for Therapeutic Radiology and Oncology (ASTRO) Annual Meeting in Washington, DC Sept. 29-Oct 2, 2024, at booth # 1937.
“We’re pleased to feature Radiant Aura at this year’s ASTRO 2024 Annual Meeting. Radiant Aura is a painless non-surgical skin cancer treatment alternative available to support the delivery of office-based radiation therapy for patients with NMSC when surgery is not possible, contraindicated, or simply not preferred due to cosmetic concerns,” said Adrian Treverton, CEO of Xstrahl.
Radiant Aura is a low-dose, X-ray based system and is the only dual modality radiation therapy system that offers both non-invasive electronic brachytherapy (eBt) and superficial radiation therapy (SRT) for treating non-melanoma skin cancers (NMSC) and keloid scarring.
Xstrahl medical director Dr. Richard Shaffer, MD, MBBS, will be available onsite at 4 PM on Sunday and Monday, Sept. 29 and 30, to provide a clinical education presentation about the clinical worldwide use of radiotherapy for the treatment of benign diseases.
Dr. Shaffer is also the president and founder of the International Organisation for Radiotherapy for Benign Conditions (IORBC). As the founding sponsor of the IORBC, Xstrahl also invites all ASTRO attendees to visit booth # 1937 to learn more this international clinical network to increase awareness of the treatment of benign conditions with radiotherapy.
ASTRO attendees will be able to learn more about the Xstrahl 200, a versatile orthovoltage radiotherapy solution for treating superficial lesions, skin cancers, and benign conditions. The Xstrahl 200 X-ray system delivers both superficial treatments and treatments at depth by combining the capability of orthovoltage X-ray systems with the traditional ease-of-use of superficial radiation therapy and is an excellent complement to a linear accelerator to add treatment capacity at a low cost.
“The Xstrahl 200 is a great addition to a linac-based cancer therapy program because it helps improve the level of patient care, treatment capacity, and the range of treatment options for patients quickly, simply, and affordably. It provides excellent maneuverability to help support the delivery of low-energy radiation treatments all over the body, which is especially important for patients with mobility issues,” Treverton added.
Xstrahl will also spotlight new internal eye shields during ASTRO. CE marked and available in four sizes, the internal eye shields are designed to be used for applications up to and including 120kV.
Visit Xstrahl at booth # 1937 at ASTRO 2024 in Washington DC, Sept. 29 through Oct. 2, 2024.
About Xstrahl
Xstrahl is a medical technology company that designs radiation delivery devices to support clinical teams and cancer researchers. For more than 25 years, Xstrahl has been shaping the development of superficial and orthovoltage radiation therapy and advancing preclinical radiation research. Xstrahl systems are in operation at more than 700 treatment and research facilities worldwide.
To learn more about Xstrahl at ASTRO 2024, visit www.com/xstrahl.com/astro-2024/
To learn more about all Xstrahl clinical and research systems, visit www.xstrahl.com
To learn more about Xstrahl eye shields, visit www.com/eye-shield-webinar
To learn more about the IORBC, visit www.iorbc.com
